Form 4: Rapport Therapeutics CSO Sells Shares Under 10b5-1 Plan

Rapport Therapeutics' Chief Scientific Officer, David Bredt, sold 8,500 shares of common stock under a pre-arranged Rule 10b5-1 trading plan.

Summary

• David Bredt, Chief Scientific Officer of Rapport Therapeutics, Inc. (RAPP), reported the sale of common stock.
• On October 15, 2025, Bredt sold 7,418 shares of common stock at a weighted average price of $25.7329 per share.
• The shares in the first transaction were sold in multiple transactions at prices ranging from $25.07 to $26.05, inclusive.
• On the same date, October 15, 2025, an additional 1,082 shares of common stock were sold at a weighted average price of $26.1641 per share.
• The shares in the second transaction were sold in multiple transactions at prices ranging from $26.07 to $26.36, inclusive.
• These transactions were executed pursuant to a Rule 10b5-1 trading plan adopted on December 12, 2024.
• Following these reported transactions, David Bredt beneficially owns 409,642 shares of common stock directly.

Sentiment

Score: 5

Explanation: The sale of shares by the Chief Scientific Officer was conducted under a pre-arranged 10b5-1 trading plan. Such plans are typically established for personal financial planning, diversification, or tax management, and do not necessarily reflect a change in the insider's outlook on the company's future performance. Therefore, the sentiment is neutral as it's a planned liquidity event.

Future Outlook

NA

Industry Context

This filing details an individual insider transaction and does not provide information directly related to broader industry trends or competitor activities. Insider sales under 10b5-1 plans are common across various industries for personal financial planning.

Stakeholder Impact

• Shareholders: May observe a slight increase in available shares on the market due to insider selling, though the impact is likely minimal given the pre-planned nature of the transaction and the relatively small percentage of total outstanding shares represented by this sale.

Key Dates

Recommendation

The filing details a pre-planned sale of shares by a Chief Scientific Officer under a Rule 10b5-1 trading plan. Such transactions are generally not indicative of new material information about the company's prospects and are often for personal financial planning. Therefore, this filing alone does not provide a basis for a change in investment recommendation, suggesting a 'hold' position for existing investors.

Keywords

Rapport Therapeutics, RAPP, Form 4, Insider Trading, Stock Sale, David Bredt, Chief Scientific Officer, 10b5-1 Plan